Clinical Spotlight: Flonase Nasal Spray for Rhinitis Management

Dr. Manisha Dadlani
19 hours ago
4 min read

Chronic inflammatory diseases of the nasal mucosa such as allergic rhinitis, rhinosinusitis, and nasal polyposis pose a significant clinical burden but can be effectively managed with topically active corticosteroids (1,2).

Allergic rhinitis is a chronic inflammatory disorder of the nasal mucosa triggered by environmental allergens (1). Allergic rhinitis is highly prevalent in India, with recent large‑scale studies showing that more than half of patients presenting with nasal complaints meet diagnostic criteria. Prevalence varies by age, gender, and region, underscoring its significant public health burden.

Persistent mucosal inflammation leads to troublesome nasal obstruction and is frequently associated with comorbidities, including asthma in up to 45% of affected individuals (2). Effective control of nasal mucosal inflammation is therefore critical to reducing both the symptomatic burden and the broader respiratory impact (1,2).

Unmet Needs

Standard medical therapy and surgical intervention often fail to provide durable, long term relief of nasal symptoms. Although surgery was once the preferred approach for severe obstruction, particularly in cases of nasal polyposis, current practice increasingly favors medical management, supported by strong evidence for the efficacy of nasal corticosteroids. Nevertheless, a therapeutic gap remains, as conventional nasal sprays may not deliver sufficient drug concentrations to the deeper sinus mucosa (2). This underscores the need for advanced delivery systems capable of achieving high local anti inflammatory activity throughout the deeper regions of the nasal cavity while minimizing systemic absorption (1,2).

Flonase Nasal Spray

Fluticasone propionate is a potent, second generation corticosteroid available as an aqueous nasal spray and nasal drops (2). Clinical studies have demonstrated that both formulations exert effective local anti inflammatory activity (1,2). In a 12 week randomized trial, each formulation was associated with significant reductions in mean nasal polyp scores (2).

Glenmark Pharmaceuticals has recently received USFDA approval for its generic version of Flonase® (fluticasone propionate) nasal spray. The product is bioequivalent and therapeutically equivalent to the reference drug, Flonase® Nasal Spray (0.05 mg/spray), and will be distributed in the U.S (3).

Benefits & Indications

Fluticasone propionate nasal spray provides effective relief for both seasonal and perennial allergic rhinitis by reducing nasal inflammation and mucus production. Its efficacy is maximized with regular, daily use rather than as an immediate rescue therapy. The key advantage of second generation intranasal corticosteroids such as fluticasone propionate lies in their highly favorable pharmacokinetic profile (1). Both spray and drop formulations demonstrate very low systemic bioavailability, thereby minimizing systemic drug exposure (1,2).

Safety & Precautions

Over three decades of clinical experience have established intranasal corticosteroids as having an excellent safety profile, with adverse reactions generally limited to mild, short lived local effects such as nasal irritation and epistaxis (1). To minimize irritation and ensure safe use, patients should follow defined device use instructions. Recommended technique includes gently shaking the bottle, removing the green cap, directing the nozzle away from the face, and depressing the lid until a fine mist is released. The nozzle should then be placed into one nostril, with the other occluded, and angled slightly away from the nasal septum while the patient inhales gently (4).

Ongoing device care is equally important. Patients should clean the nozzle once weekly to maintain accurate dosing by removing the white nozzle, rinsing it under running water, and allowing it to air dry at room temperature. A blocked nozzle should never be cleared with a pin, as this can irreversibly damage the spray mechanism. Once dry, the nozzle is pressed back into place until it clicks and is then re primed before the next use (4).

Conclusion

Chronic inflammation of the nasal mucosa presents significant clinical challenges. Fluticasone propionate formulations provide safe and highly effective local symptom relief. Aqueous nasal sprays offer consistent control of general mucosal symptoms, while twice daily nasal drops deliver superior improvements in nasal volume and restoration of olfactory function in patients with severe nasal polyposis. Strict adherence to recommended administration techniques, regular device priming, and weekly nozzle cleaning are essential to ensure patients safely achieve the full therapeutic benefit of fluticasone propionate.

About the Author

Dr. Manisha Dadlani is a Dental Surgeon and Medical Writer with 5+ years of clinical experience and formal training in medical writing. She combines clinical expertise with analytical thinking to develop evidence-based, insight-driven content that supports effective scientific communication across the healthcare and life sciences landscape.

References

Sastre J, Mosges R. Local and systemic safety of intranasal corticosteroids. J Investig Allergol Clin Immunol. 2012;22(1):1-12 https://pubmed.ncbi.nlm.nih.gov/22448448/
Demirel T, Orhan KS, Keleş Türel MN, Değer K. Comparison of the efficacy of nasal drop and nasal spray applications of fluticasone propionate in nasal polyps. The Turkish Journal of Ear Nose and Throat. 2008;18(1):1-6 https://iupress.istanbul.edu.tr/journal/tr-ent/article/comparison-of-the-efficacy-of-nasal-drop-and-nasal-spray-applications-of-fluticasone-propionate-in-nasal-polyps
Glenmark gets USFDA nod for generic fluticasone propionate nasal spray. Available at: https://www.thehindubusinessline.com/companies/glenmark-gets-usfda-nod-for-generic-fluticasone-propionate-nasal-spray/article71367780.ece Accessed on 1st September, 2026.
Flonase Nasal Spray. Available at: https://www.flonase.com/products/flonase-allergy-relief/ Accessed on 1st September, 2026.

Disclaimer

The matter published on this platform has been developed by independent medical writers from various healthcare backgrounds including members of MedWriters Alumni Network. Although great care has been taken in compiling and checking the information, the authors, Rxnews team and its partners or agents, and sponsors shall not be responsible or in any way liable for any errors, omissions, or inaccuracies in this blog article whether arising from negligence or otherwise, however or for any consequences arising therefrom. The inclusion and exclusion of any product do not mention that the publisher advocates or rejects its use generally or in any particular field. For any complaints or feedback please write to contact@crixus.co.in